A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants
Status:
Recruiting
Trial end date:
2022-03-23
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to compare the amount of mirikizumab that gets into the
blood stream and how long it takes the body to get rid of it, when given as a solution
formulation via manual prefilled syringe or autoinjector. The information about any adverse
effects experienced will be collected and the tolerability of mirikizumab will also be
evaluated.
Screening is required within 28 days prior to the enrolment. For each participant, the total
duration of the clinical trial will be about 17 weeks including screening.